Table 2.
Demographics by trial.
| Trial | Basket Trial | Sarcoma Trial |
|---|---|---|
| Total patients | 137 | 59 |
| Tumour type, N (%)a | ||
| Breast | 61 (45%) | 0 (0%) |
| Liposarcoma | 1 (<1%) | 59 (100%) |
| Germ cell | 30 (22%) | 0 (0%) |
| Colorectal | 22 (16%) | 0 (0%) |
| Oesophageal | 12 (9%) | 0 (0%) |
| Otherb | 11 (6%) | 0 (0%) |
| Age in years, median (range)a | 56 (17–88) | 62 (35–87) |
| Gender, N (%) | ||
| Female | 80 (58%) | 29 (49%) |
| Male | 57 (42%) | 30 (51%) |
| Race, N (%) | ||
| White | 122 (89%) | 47 (79%) |
| Black | 8 (6%) | 4 (7%) |
| Asian/other | 7 (5%) | 8 (14%) |
| BMI, median (range)c | 25.8 (16.0–47.1) | 27.2 (17.5–48.0) |
| Baseline ECOG PS, N (%)a | ||
| 0 | 71 (52%) | 51 (86%) |
| 1 | 66 (48%) | 8 (14%) |
| # Prior lines of therapy, N (%)a | ||
| 0 | 2 (1%) | 22 (37%) |
| 1 | 23 (17%) | 29 (49%) |
| 2 | 23 (17%) | 4 (7%) |
| ≥3 | 89 (65%) | 4 (7%) |
| Immediate prior line chemotherapy, N (%)a | ||
| Yes | 38 (28%) | 37 (63%) |
| No | 99 (72%) | 22 (37%) |
| Baseline ANC (K/μL), median (range) | 4.2 (1.5–31.9) | 4.1 (1.5–10.2) |
aFisher’s Exact p < 0.05 (Wilcoxon rank-sum used for age, BMI, and baseline ANC).
bOthers are diagnoses representing <5% of all patients (adrenal, gastric, glioblastoma, renal cell, and thymus cancers).
cMissing BMI values for two patients in Basket Trial (due to unrecorded height).